Atea Pharmaceuticals, Inc.
AVIR
$3.06
-$0.04-1.29%
| Weiss Ratings | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.85 | |||
| Price History | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 5.52% | |||
| 30-Day Total Return | 2.00% | |||
| 60-Day Total Return | 3.73% | |||
| 90-Day Total Return | -6.71% | |||
| Year to Date Total Return | -10.53% | |||
| 1-Year Total Return | -23.31% | |||
| 2-Year Total Return | -9.20% | |||
| 3-Year Total Return | -44.36% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -25.21% | |||
| 52-Week Low % Change | 12.73% | |||
| Price | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.15 | |||
| 52-Week Low Price | $2.75 | |||
| 52-Week Low Price (Date) | Dec 10, 2024 | |||
| 52-Week High Price (Date) | Sep 17, 2024 | |||
| Valuation | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 265.13M | |||
| Enterprise Value | -187.95M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.00 | |||
| Earnings Per Share Growth | 22.67% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.60 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $3.06 | |||
| Enterprise Value/EBITDA (TTM) | 1.10 | |||
| Enterprise Value/EBIT | 1.10 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 84.46M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 284 8891 | |||
| Address | 225 Franklin Street Boston, MA 02110 | |||
| Website | ateapharma.com | |||
| Country | United States | |||
| Year Founded | 2012 | |||
| Profitability | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -20.23% | |||
| Return on Equity | -- | |||
| Income Statement | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -122.62M | |||
| EBITDA (TTM) | -171.05M | |||
| EBIT (TTM) | -171.47M | |||
| Net Income (TTM) | -168.39M | |||
| Net Income Avl. to Common (TTM) | -168.39M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 14.35% | |||
| EPS Diluted (TTM) | -2.00 | |||
| EPS Diluted Growth (Q YOY) | 15.40% | |||
| Balance Sheet | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 454.72M | |||
| Cash Per Share (Q) | $5.38 | |||
| Total Current Assets (Q) | 462.36M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 438.87M | |||
| Current Ratio (Q) | 24.854 | |||
| Book Value Per Share (Q) | $5.20 | |||
| Total Assets (Q) | 464.67M | |||
| Total Current Liabilities (Q) | 18.60M | |||
| Total Debt (Q) | 1.64M | |||
| Total Liabilities (Q) | 25.80M | |||
| Total Common Equity (Q) | 438.87M | |||
| Cash Flow | AVIR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 56.11M | |||
| Cash from Financing (TTM) | 267.00K | |||
| Net Change in Cash (TTM) | -79.13M | |||
| Levered Free Cash Flow (TTM) | -64.08M | |||
| Cash from Operations (TTM) | -135.50M | |||
